NeurologicalICD-10: G24.01Affects approximately 20-30% of patients on long-term antipsychotic therapy

Tardive Dyskinesia

Also known as: TD

Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive facial and body movements, most commonly caused by long-term use of dopamine-blocking medications such as antipsychotics. Movements often involve the face, tongue, and jaw but can affect the limbs and trunk. Early recognition and medication adjustment are critical, and FDA-approved treatments are now available.

Last updated November 10, 2026

Understanding Tardive Dyskinesia

Tardive dyskinesia (TD) is a movement disorder of involuntary, repetitive movements, most often of the mouth, tongue and jaw, that appears after months or years of taking a medication that blocks dopamine receptors. 'Tardive' means late: by definition the movements emerge after at least three months of exposure, or one month in adults over 60. Antipsychotics are the usual cause, but the anti-nausea drugs metoclopramide, prochlorperazine and promethazine can do the same. Pooled data from 41 studies covering more than 11,000 people put the prevalence at about 25 percent of those on long-term antipsychotic treatment, roughly 30 percent with older first-generation drugs and 21 percent with second-generation drugs. The risk accumulates at about 3 to 5 percent per year of exposure in younger adults and far faster after 55: in older adults started on a first-generation antipsychotic, one in four develops TD within a year and half within three. An estimated 500,000 to 600,000 Americans live with it, and about half do not notice the movements themselves.

Dopamine-blocking drugs quiet the D2 receptors in the striatum, the part of the brain that fine-tunes movement. Over months the brain compensates by adding receptors and making them more sensitive, and the blocked circuits also suffer oxidative stress and maladaptive rewiring of their synapses. When the blockade is loosened by a missed dose, a dose reduction or stopping the drug, the oversensitive system fires in bursts, which is why TD can first appear or briefly worsen after a dose change. The movements are typically chewing, lip-pursing, tongue-rolling or grimacing, but the fingers, trunk and even the breathing muscles can be involved, and a related form, tardive dystonia, causes sustained twisting postures. Left alone, TD is usually persistent: in a university movement-disorder clinic series of 108 patients, only 2 percent had complete resolution and 13 percent improved after the offending drug was stopped. Remission is more likely in younger people whose TD is caught early and who can come off the drug.

The evidence-based treatment is a VMAT2 inhibitor, which reduces dopamine release from nerve terminals and so calms the oversensitive receptors. Two are FDA-approved for TD. In the 6-week KINECT 3 trial of 234 adults, valbenazine 80 mg lowered the Abnormal Involuntary Movement Scale (AIMS) score by 3.2 points against 0.1 on placebo, and 40 percent of patients achieved at least a 50 percent reduction compared with 9 percent on placebo. In the 12-week ARM-TD trial of 117 adults, deutetrabenazine lowered AIMS by 3.0 points against 1.6, and the 298-person AIM-TD trial confirmed a dose response. Benefit keeps building over a year of treatment. The American Academy of Neurology (AAN) rates both as Level A, and the 2020 American Psychiatric Association (APA) schizophrenia guideline recommends one for moderate to severe or disabling TD. Side effects include sleepiness, parkinsonism and, for the older related drug tetrabenazine, a boxed warning for depression and suicidality. Clonazepam has Level B evidence for short-term relief and amantadine Level C. Anticholinergics such as benztropine, prescribed for drug-induced stiffness, make TD worse and should be tapered.

Supplements occupy a modest place behind the VMAT2 inhibitors, and the honest ranking is short. Ginkgo biloba extract has the best data: a single 12-week Chinese trial of 157 inpatients with schizophrenia found that 240 mg a day lowered AIMS scores by about 2 points more than placebo, enough for the AAN to grade it Level B, but it has never been replicated outside that one population. Vitamin E was popular in the 1990s on the theory that TD is an oxidative injury; a Cochrane review of 13 trials involving 478 people concluded it does not improve established movements, though it may slow deterioration, and rated the evidence quality low. Vitamin B6 has two small trials from one Israeli group at doses high enough to cause their own nerve damage, melatonin has one 22-person crossover trial, and branched-chain amino acids a handful of tiny studies. Omega-3 (EPA) failed in an 84-person trial. None of these should delay a conversation about valbenazine or deutetrabenazine when the movements are bothersome or progressing.

The most common mistake is stopping the antipsychotic suddenly once the movements are spotted. Abrupt withdrawal often makes the dyskinesia temporarily worse (withdrawal-emergent dyskinesia) and sharply raises the chance of a psychiatric relapse, which in schizophrenia or bipolar disorder can be far more dangerous than the movements. The second mistake is quietly tolerating TD because the underlying illness is finally stable; screening is patchy, many patients cannot see their own movements, and a family member is often the first to mention them. The better path is a planned conversation with the prescriber about an AIMS examination, whether a lower dose or a lower-risk drug such as clozapine or quetiapine is realistic, whether any anticholinergic can be tapered, and whether a VMAT2 inhibitor is warranted. Ask that the exam be repeated every 6 months on a first-generation drug and every 12 months on a second-generation drug, which is what the APA recommends, and sooner if you are over 55 or have diabetes.

At a Glance

Common symptoms
Repetitive lip smacking or puckering, Tongue protrusion or rolling, Rapid eye blinking
Main treatments
VMAT2 inhibitors such as valbenazine or deutetrabenazine (FDA-approved treatments), Switching to a lower-risk antipsychotic if possible, Gradual dose reduction of the causative medication under medical supervision
Category
Neurological · Affects approximately 20-30% of patients on long-term antipsychotic therapy
See a doctor if
Any new involuntary movements while taking antipsychotic or antiemetic medications

Symptoms

Repetitive lip smacking or puckering
Tongue protrusion or rolling
Rapid eye blinking
Facial grimacing
Involuntary jaw movements
Finger movements or toe tapping
Rocking or swaying of the trunk

Causes

  • Prolonged use of dopamine receptor-blocking medications, especially first-generation antipsychotics
  • Dopamine receptor hypersensitivity from chronic blockade
  • Antiemetic medications such as metoclopramide

Risk Factors

  • Duration and dose of antipsychotic medication
  • Older age, especially postmenopausal women
  • Female sex
  • History of mood disorders
  • Substance use disorder
  • Use of first-generation antipsychotics

Diagnosis

  • Clinical observation of characteristic involuntary movements
  • Abnormal Involuntary Movement Scale (AIMS) assessment
  • Medication history review
  • Ruling out other movement disorders such as Huntington's disease

Treatment

  • VMAT2 inhibitors such as valbenazine or deutetrabenazine (FDA-approved treatments)
  • Switching to a lower-risk antipsychotic if possible
  • Gradual dose reduction of the causative medication under medical supervision
  • Avoiding abrupt discontinuation which may temporarily worsen symptoms

Natural remedies for tardive dyskinesia: what the evidence says

Ranked by the strength of human evidence for tardive dyskinesia specifically. These sit alongside medical care, not in place of it.

  1. Ginkgo Biloba

    Moderate evidence

    In a 12-week randomized trial of 157 inpatients with schizophrenia and TD, the standardized extract EGb 761 at 240 mg a day lowered AIMS scores by 2.1 points versus 0.1 on placebo, and 51 percent of the ginkgo group improved by at least 30 percent compared with 5 percent on placebo. The American Academy of Neurology graded this Level B, the only supplement to reach that tier. It remains a single trial from one center and has not been repeated in the United States or in people taking second-generation antipsychotics.

    Studied dose
    240 mg a day of a standardized extract (24 percent flavone glycosides, 6 percent terpene lactones), as 80 mg three times daily or 120 mg twice daily, for at least 12 weeks.
    Cautions
    Raises bleeding risk with warfarin, aspirin, clopidogrel and NSAIDs, and should be stopped 2 weeks before surgery. Seizures have been reported in case series, and several antipsychotics, clozapine especially, already lower the seizure threshold. It can alter blood levels of omeprazole and other drugs cleared by CYP2C19. Avoid in pregnancy.
  2. Vitamin E

    Preliminary evidence

    A 2018 Cochrane review pooled 13 randomized trials with 478 participants taking 400 to 1,600 IU a day for 4 weeks to 2 years. Vitamin E did not produce clinically important improvement in existing movements, although fewer people deteriorated while taking it. The reviewers rated the overall quality of evidence as low, and the AAN lists vitamin E as Level U, meaning the data are insufficient to recommend it.

    Studied dose
    Trials used 400 to 1,600 IU of alpha-tocopherol daily; there is no reason to go above 400 IU, and the benefit at any dose is uncertain.
    Cautions
    Doses of 400 IU and above were linked to a small increase in all-cause mortality in a 2005 meta-analysis and to a 17 percent higher prostate cancer risk in the 35,000-man SELECT trial. It increases bleeding with warfarin and antiplatelet drugs and should be stopped before surgery.
  3. Vitamin B6 (Pyridoxine)

    Preliminary evidence

    Two crossover trials from one Israeli group are the evidence: 15 inpatients given 400 mg a day for 4 weeks, and 50 inpatients given 1,200 mg a day for 26 weeks, both showed improvement on the Extrapyramidal Symptom Rating Scale. A 2015 Cochrane review found only 80 participants across all trials and rated the evidence very low quality. The doses used are 4 to 12 times the safe upper limit.

    Studied dose
    Trials used 400 to 1,200 mg of pyridoxine daily. The US tolerable upper intake is 100 mg a day, so trial-level dosing should only happen under medical supervision.
    Cautions
    Pyridoxine above 200 mg a day for months causes a sensory neuropathy (numb, burning feet and unsteady walking), and cases have been reported at lower doses taken for years. It reduces the effect of levodopa given without carbidopa and can lower phenytoin and phenobarbital levels.
  4. Melatonin

    Preliminary evidence

    In a 6-week crossover trial of 22 patients with schizophrenia and TD, 10 mg of controlled-release melatonin at night reduced AIMS scores by 2.45 points versus 0.77 on placebo. An earlier trial by the same group using 2 mg found no effect, and a later 13-person study using 20 mg was negative, so the signal is inconsistent and the total evidence base is under 60 people.

    Studied dose
    10 mg controlled-release melatonin at bedtime for 6 weeks was the dose in the positive trial.
    Cautions
    Adds to the sedation of antipsychotics, benzodiazepines and sedating antidepressants. Fluvoxamine raises melatonin blood levels many-fold. It can increase bleeding risk with warfarin and may worsen mood in some people with depression. US supplement content is unreliable, so choose a third-party verified product.

What matters day to day

  • Ask for a documented AIMS examination on a schedule, every 6 months on a first-generation antipsychotic and every 12 months on a second-generation drug: TD caught in its first year is far more likely to remit than TD found after five, and about half of patients cannot see their own movements.
  • Never stop or skip your antipsychotic on your own after noticing movements: abrupt withdrawal commonly worsens dyskinesia for weeks and raises relapse risk several-fold, so any dose change should be planned with the prescriber.
  • Audit every dopamine-blocking drug you take, not just the psychiatric ones: metoclopramide carries an FDA boxed warning for TD and should not be used beyond 12 weeks, and prochlorperazine and promethazine for nausea carry the same risk.
  • Ask whether an anticholinergic such as benztropine or trihexyphenidyl can be tapered: these help drug-induced tremor and stiffness but reliably make tardive movements worse.
  • Stop smoking and keep blood sugar in range: smokers and people with diabetes have consistently higher TD rates in cohort studies, and antipsychotics themselves raise glucose, so an annual A1c is reasonable.
  • Expect movements to worsen with stress, fatigue, caffeine and stimulants and to disappear in sleep: tracking what amplifies them helps you and your clinician judge whether treatment is working rather than reacting to a bad day.

Prevention

  • Using the lowest effective dose of antipsychotic medications
  • Regular monitoring for early signs of involuntary movements
  • Preferring second-generation antipsychotics with lower TD risk when appropriate
  • Periodic reassessment of the need for antipsychotic therapy

When to See a Doctor

  • Any new involuntary movements while taking antipsychotic or antiemetic medications
  • Movements that persist after stopping medication
  • Symptoms affecting eating, speaking, or daily functioning

Frequently Asked Questions

References

  1. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. Journal of Clinical Psychiatry (2017)
  2. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry (2018)
  3. Bhidayasiri R, Fahn S, Weiner WJ, et al.. Evidence-based guideline: treatment of tardive syndromes. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2013)
  4. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences (2018)
  5. Hauser RA, Factor SA, Marder SR, et al.. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of Psychiatry (2017)
  6. Fernandez HH, Factor SA, Hauser RA, et al.. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology (2017)
  7. Zhang WF, Tan YL, Zhang XY, et al.. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry (2011)
  8. Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews (2018)
  9. Keepers GA, Fochtmann LJ, Anzia JM, et al.. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry (2020)
  10. National Institute of Neurological Disorders and Stroke. Tardive Dyskinesia (2024)View source

Related Conditions

Have questions about Tardive Dyskinesia?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.